Tower Research Capital LLC TRC Has $3.89 Million Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Tower Research Capital LLC TRC boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 316.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,044 shares of the medical instruments supplier’s stock after acquiring an additional 8,393 shares during the quarter. Tower Research Capital LLC TRC’s holdings in West Pharmaceutical Services were worth $3,889,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of WST. Planned Solutions Inc. acquired a new stake in West Pharmaceutical Services during the 4th quarter worth about $39,000. Addison Advisors LLC boosted its position in West Pharmaceutical Services by 28.9% during the 4th quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 41 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its position in West Pharmaceutical Services by 90.0% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 90 shares during the period. Lindbrook Capital LLC boosted its position in West Pharmaceutical Services by 46.0% during the 4th quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock worth $83,000 after acquiring an additional 74 shares during the period. Finally, Tompkins Financial Corp acquired a new stake in West Pharmaceutical Services during the 4th quarter worth about $89,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Down 0.1 %

WST opened at $314.76 on Friday. The business has a 50 day moving average price of $361.29 and a 200 day moving average price of $362.79. West Pharmaceutical Services, Inc. has a twelve month low of $310.42 and a twelve month high of $415.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. The firm has a market cap of $22.93 billion, a P/E ratio of 41.53, a price-to-earnings-growth ratio of 5.57 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last posted its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The firm had revenue of $695.40 million during the quarter, compared to analyst estimates of $670.62 million. During the same period in the previous year, the company earned $1.98 EPS. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Research analysts forecast that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.55%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on WST shares. UBS Group reduced their price target on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a report on Friday, February 16th. StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, February 16th. Finally, KeyCorp lifted their price target on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a report on Tuesday, February 13th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $435.20.

View Our Latest Report on West Pharmaceutical Services

Insider Transactions at West Pharmaceutical Services

In other news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the transaction, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the transaction, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.